アブストラクト
Title | 2. SGLT2阻害薬と心血管イベント - 心不全の発症・進行抑制 - |
---|---|
Subtitle | 特集 SGLT2阻害薬Update |
Authors | 八木秀介, 佐田政隆* |
Authors (kana) | |
Organization | *徳島大学大学院医歯薬学研究部循環器内科学 |
Journal | PROGRESS IN MEDICINE |
Volume | 40 |
Number | 2 |
Page | 109-115 |
Year/Month | 2020 / 2 |
Article | 報告 |
Publisher | ライフ・サイエンス |
Abstract | 「はじめに」Sodium-glucose cotransporter 2 (SGLT2) 阻害薬の心血管アウトカム試験のエビデンスが出揃い, SGLT2阻害薬の心腎保護効果, 特に心不全抑制効果が明らかとなり, SGLT2阻害薬が2型糖尿病に対して広く使用されるようになった. SGLT2阻害薬は, 近位尿細管にてグルコース再吸収を抑制することによる血糖降下作用を発揮するが, その他にも, 浸透圧利尿やナトリウム (Na) 利尿を介した体重減少・降圧効果・脂質改善・尿酸低下作用などがある. これらの多面的効果が複合的に作用して心血管保護効果につながると考えられる. 糖尿病の治療目標は, 健康な人と変わらない日常生活の質の維持と寿命を確保することであり, 心血管合併症予防のためには, 血糖のみならず, 体重・血圧・脂質の良好なコントロール状態の維持を行うことが重要である. |
Practice | 医学総合 |
Keywords |
- 全文ダウンロード: 従量制、基本料金制の方共に968円(税込) です。
参考文献
- 1) Zinman B, Wanner C, Lachin JM, et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.
- 2) Fitchett D, Zinman B, Wanner C, et al: Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 2016;37:1526-1534.
- 3) Fitchett D, Butler J, van de Borne P, et al: Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 2018;39:363-370.
- 4) Savarese G, Sattar N, Januzzi J, et al: Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality. Circulation 2019;139:1458-1460.
- 5) Neal B, Perkovic V, Matthews DR: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:2099.
残りの11件を表示する
- 6) Mahaffey KW, Neal B, Perkovic V, et al: Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018;137:323-334.
- 7) Figtree GA, Radholm K, Barrett TD, et al: Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation 2019;139:2591-2593.
- 8) Wiviott SD, Raz I, Sabatine MS: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. reply. N Engl J Med 2019;380:1881-1882.
- 9) Zelniker TA, Wiviott SD, Raz I, et al: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-39.
- 10) Kosiborod M, Cavender MA, Fu AZ, et al: Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL Study (Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 2017;136:249-259.
- 11) Baartscheer A, Schumacher CA, Wust RC, et al: Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 2017;60:568-573.
- 12) Staels B: Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol 2017;120:S28-S36.
- 13) Nerlekar N, Muthalaly RG, Wong N, et al: Association of volumetric epicardial adipose tissue quantification and cardiac structure and function. J Am Heart Assoc 2018;7:e009975.
- 14) Yagi S, Hirata Y, Ise T, et al: Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2017;9:78.
- 15) Verma S, Mazer CD, Yan AT, et al: Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation 2019;140:1693-1702.
- 16) Pabel S, Wagner S, Bollenberg H, et al: Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail 2018;20:1690-1700.